Home > Oncology > ASCO 2021 > Gastrointestinal Cancers > Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective

Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective

Presented By
Prof. John Reynolds, Trinity St James Cancer Institute, Ireland
Conference
ASCO 2021
Trial
Phase 3, Neo-AEGIS
First results of the phase 3, open-label Neo-AEGIS trial demonstrated no evidence that perioperative chemotherapy (i.e. modified MAGIC or FLOT regimen) was inferior to multimodal therapy (i.e. CROSS regimen) in patients with oesophageal adenocarcinoma (EAC) and gastric-oesophageal junction cancer (GEJ). The optimum combination curative approach to locally advanced GEJ/EAC is unknown. A key question is whether neoadjuvant multimodal therapy, specifically the CROSS regimen (i.e. carboplatin/paclitaxel, 41.4 Gy radiation therapy), is superior to optimum perioperative chemotherapeutic regimens including modified MAGIC (i.e. epirubicin, cisplatin [oxaliplatin], 5-FU [capecitabine]) and more recently FLOT (i.e. docetaxel, 5-FU, leucovorin, oxaliplatin). The Neo-AEGIS trial (NCT01726452) is the first randomised controlled trial designed to address this ques...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on